Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Opsiria (sirolimus)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

MacuSight, Santen

Drug class:

mTOR inhibitor

Related drugs:

›

EGFR P753S	Squamous Cell Carcinoma of Head and Neck	EGFR P753S	Squamous Cell Carcinoma of Head and Neck	cetuximab + sirolimus Sensitive: C4 – Case Studies cetuximab + sirolimus Sensitive : C4	cetuximab + sirolimus Sensitive: C4 – Case Studies cetuximab + sirolimus Sensitive : C4
FBXW7 G499Vfs*25	Colorectal Cancer	FBXW7 G499Vfs*25	Colorectal Cancer	sirolimus Resistant: C4 – Case Studies sirolimus Resistant : C4	sirolimus Resistant: C4 – Case Studies sirolimus Resistant : C4
MTOR S2215Y	Endometrial Cancer	MTOR S2215Y	Endometrial Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
MTOR E1799K	Endometrial Cancer	MTOR E1799K	Endometrial Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
PIK3CA E542K	Breast Cancer	PIK3CA E542K	Breast Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
MTOR F2108L	Breast Cancer	MTOR F2108L	Breast Cancer	sirolimus Resistant: D – Preclinical sirolimus Resistant : D	sirolimus Resistant: D – Preclinical sirolimus Resistant : D
MTOR M2327I	Breast Cancer	MTOR M2327I	Breast Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
FLCN deletion	Renal Cell Carcinoma	FLCN deletion	Renal Cell Carcinoma	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D